I dont see why one would take the path of a proper drug approval if there is now this less rigorous, alternative path to market, he said
doi: 10.1097/SHK.0000000000001941 64 XuWWuYWangSHuSWangYZhouWet al
If traveling internationally, research the destination country's specific regulations on GLP-1 medications, as some nations restrict certain compounded medications or require additional customs documentation
Very interesting paper providing cardiologists point of view on the comparison of semaglutude and tirzepatide They conclude that semaglutide currently remains the most established option for reducing cardiovascular risk in patients with T2DM and obesity with atherosclerotic disease Tirzepatide is particularly well suited when maximal weight reduction represents the primary clinical objective
Regardless of what medication is inside
MANTZ, J.M., TEMPE, J.D., JAEGER, A., & VIDAL, S